Vol 15, No 3 (2019)
Other materials agreed with the Editors
Published online: 2019-06-26
Current literature review
Oncol Clin Pract 2019;15(3):190-193.
Abstract
Not available
Article available in PDF format
Purchase SubscriptionReferences
- Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–1825.
- Dahan L, Phelip J, Malicot KLe, et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). Journal of Clinical Oncology. 2018; 36(15_suppl): 4000.
- Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline-mutated metastatic pancreatic cancer. N Engl J Med. 2019 [Epub ahead of print].
- Hall P, Swinson D, Waters J, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. Journal of Clinical Oncology. 2019; 37(15_suppl): 4006.
- Buckner J, Shaw E, Pugh S, et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. New England Journal of Medicine. 2016; 374(14): 1344–1355.
- Bell E, Won M, Fleming J, et al. Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802. J Clin Oncol. 2019; 37(15_suppl): 2002.